The companies will work together to create an end-to-end workflow for biomarker and drug target validation, and assay development.
The company will provide oncology specimens and associated clinical data to the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium.
5AM Solutions will develop software that will allow Asterand to electronically link multiple biorepositories and identify, annotate, and distribute biospecimen data internally and with collaborators.
The contract to supply biospecimens for the Cancer Genome Atlas project could reach a total value of $24 million.
BioSeek will apply its BioMap predictive human disease models to screen Amylin's library.
The Japanese pharmaceutical developer has licensed the BioMap platform for drug toxicology research projects.
BioSeek will use its BioMap system to conduct screening for Ono Pharmaceuticals in its compound studies.
Affymetrix, Febit, Asterand, ImaGenes
BMS will continue to use Asterand's tissue-based drug-discovery products and services for up to three years.
The acquisition will combine Asterand's tissue-based services for drug discovery with BioSeek's BioMap platform and human cell-based assays.
Senator Lamar Alexander (R-Tenn.), who chairs the Senate health committee, will be retiring at the end of his term, Stat News reports.
The Wall Street Journal reports on the US Centers for Disease Control and Prevention's use of genetic approaches to study foodborne illnesses.
UCSF researchers find that having two X chromosomes may contribute to women's longer lifespans, according to Discover's D-brief blog.
In PNAS this week: immune cell profiling of wild baboons by social status, metabolomics profiling of esophageal tumors, and more.